53Biologics featured in APTE Technonews for its innovation in RNA enzyme production

53Biologics has been featured in the latest edition of APTE Technonews (Issue 91), the magazine of the Spanish Association of Science and Technology Parks. The article highlights our contribution to innovation in RNA enzyme manufacturing. This is a cornerstone technology enabling mRNA vaccines, gene therapy and next-generation RNA-based treatments.The challenge of RNA enzyme manufacturing

RNA-based therapeutics rely on high-performance enzymes such as RNA polymerase, essential for accurate RNA synthesis. However, manufacturing these enzymes at industrial scale poses major challenges related to purity, catalytic activity and scalability. Optimizing expression, purification and formulation conditions is critical to ensure consistent performance and regulatory compliance.

53Biologics: A partner in RNA innovation

As a CDMO specialized in biologics production from DNA to proteins, 53Biologics has developed a flexible and scalable approach for RNA enzyme manufacturing. The company has improved process flexibility, minimized cross-contamination risks and enhanced production efficiency.

Their facilities support multiple production scales, from 500 L non-GMP to 200 L and 2,000 L GMP batches. This allows them to adapt to each client’s project stage and regulatory pathway. This modularity ensures seamless transitions from preclinical development to full GMP manufacturing.

Driving the future of RNA-based therapies

Ongoing R&D at 53Biologics focuses on improving enzyme stability, catalytic efficiency and formulation to expand their use in RNA-based therapies, vaccines, and genetic-editing tools. With our experience and technological capabilities, they continue to support the development of more accessible and effective RNA therapeutics worldwide.